Field Trip Health & Wellness Ltd. (FTHWF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Field Trip Health & Wellness Ltd. (FTHWF) with AI Score 38/100 (Weak). Field Trip Health & Wellness Ltd. operates health centers providing psychedelic therapies in North America and Europe. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 18, 2026Field Trip Health & Wellness Ltd. (FTHWF) Healthcare & Pipeline Overview
Field Trip Health & Wellness Ltd. is a biotechnology company focused on psychedelic therapies, operating health centers across North America and Europe. With a presence in a niche market, the company aims to provide innovative treatments for mental health, but faces challenges typical of early-stage biotech firms.
Investment Thesis
Field Trip Health & Wellness Ltd. presents a speculative investment opportunity within the emerging psychedelic therapy market. The company's focus on developing and delivering psychedelic-assisted treatments for mental health conditions positions it to capitalize on the growing acceptance and legalization of these therapies. Key value drivers include the expansion of its health center network and the development of proprietary psychedelic molecules. However, the company faces significant risks, including regulatory hurdles, competition from other biotech firms, and the need for substantial capital investment. With a current P/E ratio of -0.34 and no dividend, the company's financial performance is closely tied to its ability to successfully navigate these challenges and achieve commercial success. The absence of a market cap suggests significant volatility and uncertainty. Investors should carefully consider these factors before investing.
Based on FMP financials and quantitative analysis
Key Highlights
- Operates health centers providing psychedelic therapies in North America and Europe.
- Focuses on developing innovative treatments for mental health conditions.
- Based in Toronto, Canada, indicating a North American operational focus.
- P/E ratio of -0.34 reflects current losses and the early stage of the company.
- No dividend yield, typical for growth-focused biotechnology companies reinvesting earnings.
Competitors & Peers
Strengths
- First-mover advantage in the psychedelic therapy market.
- Established network of health centers.
- Focus on research and development of proprietary molecules.
- Experienced management team with expertise in biotechnology and healthcare.
Weaknesses
- Limited operating history and financial resources.
- Dependence on regulatory approvals for market expansion.
- High capital expenditure requirements for research and development.
- Negative P/E ratio indicates current losses.
Catalysts
- Upcoming: Regulatory approvals for psychedelic therapies in key jurisdictions could expand market access.
- Ongoing: Expansion of the health center network to new locations in North America and Europe.
- Ongoing: Progress in clinical trials for proprietary psychedelic molecules.
- Ongoing: Strategic partnerships with pharmaceutical companies and research institutions.
- Ongoing: Increasing public awareness and acceptance of psychedelic treatments.
Risks
- Potential: Regulatory hurdles and evolving legal landscape could delay or prevent market expansion.
- Potential: Competition from other biotechnology companies in the psychedelic therapy market.
- Potential: Adverse side effects and safety concerns associated with psychedelic substances.
- Potential: Negative public perception and stigma associated with psychedelic treatments.
- Ongoing: Dependence on securing funding and achieving commercial success.
Growth Opportunities
- Expansion of Health Center Network: Field Trip has the opportunity to expand its network of health centers across North America and Europe. Each new center increases the company's capacity to deliver psychedelic therapies and generate revenue. The market for mental health treatments is substantial, with an estimated value of $100 billion globally. Successful expansion depends on securing necessary regulatory approvals and managing operational costs effectively. The timeline for expansion is ongoing, with new centers planned for key metropolitan areas over the next 3-5 years.
- Development of Proprietary Psychedelic Molecules: Investing in research and development to create proprietary psychedelic molecules offers a significant growth opportunity. Patent protection on these molecules could provide a competitive advantage and generate substantial revenue streams. The market for novel therapeutics is highly lucrative, with successful drugs often achieving blockbuster status. This development is an ongoing process, with initial clinical trials expected to begin within the next 2 years.
- Strategic Partnerships and Collaborations: Forming strategic partnerships with pharmaceutical companies, research institutions, and other healthcare providers can accelerate the development and commercialization of psychedelic therapies. These partnerships can provide access to funding, expertise, and distribution channels. The market for collaborative drug development is robust, with numerous examples of successful partnerships in the biotechnology industry. The timeline for establishing these partnerships is immediate, with ongoing discussions with potential collaborators.
- Increased Public Awareness and Acceptance: As public awareness and acceptance of psychedelic therapies increase, the demand for Field Trip's services is likely to grow. Educating the public about the potential benefits of these therapies can help to reduce stigma and encourage more people to seek treatment. The market for mental health education and awareness is expanding, with various organizations working to promote mental wellness. This is an ongoing effort, with continuous outreach and engagement activities planned.
- Regulatory Approvals and Legalization: Obtaining regulatory approvals for psychedelic therapies in various jurisdictions is crucial for long-term growth. As more countries and states legalize or decriminalize these substances, the market for Field Trip's services will expand. The regulatory landscape is evolving, with ongoing discussions and legislative initiatives in several regions. The timeline for achieving these approvals varies, but significant progress is expected over the next 5-10 years.
Opportunities
- Expanding health center network across North America and Europe.
- Securing regulatory approvals for psychedelic therapies in various jurisdictions.
- Forming strategic partnerships with pharmaceutical companies and research institutions.
- Increasing public awareness and acceptance of psychedelic treatments.
Threats
- Regulatory hurdles and evolving legal landscape.
- Competition from other biotechnology companies in the psychedelic therapy market.
- Potential for adverse side effects and safety concerns.
- Negative public perception and stigma associated with psychedelic substances.
Competitive Advantages
- First-mover advantage in the emerging psychedelic therapy market.
- Proprietary treatment protocols and therapeutic approaches.
- Established network of health centers providing specialized care.
- Investment in research and development to create proprietary psychedelic molecules.
About FTHWF
Field Trip Health & Wellness Ltd., based in Toronto, Canada, is dedicated to the development and delivery of psychedelic therapies. The company operates health centers in North America and Europe, providing treatments for mental health conditions. Founded with the vision of transforming mental healthcare through psychedelic-assisted therapy, Field Trip aims to address conditions such as depression, anxiety, and PTSD. The company's approach involves combining psychedelic substances, such as psilocybin and ketamine, with psychotherapy to enhance treatment outcomes. Field Trip's health centers offer a controlled and supportive environment for these therapies, ensuring patient safety and comfort. The company also invests in research and development to explore new psychedelic compounds and treatment protocols. Field Trip's strategy includes expanding its network of health centers and developing proprietary psychedelic molecules. The company seeks to establish itself as a leader in the emerging field of psychedelic medicine, providing innovative and effective treatments for mental health disorders. As of 2026, Field Trip continues to navigate the regulatory landscape and build its clinical infrastructure to support the growing demand for psychedelic therapies.
What They Do
- Operates health centers that provide psychedelic therapies.
- Offers treatments for mental health conditions such as depression, anxiety, and PTSD.
- Combines psychedelic substances with psychotherapy to enhance treatment outcomes.
- Provides a controlled and supportive environment for psychedelic therapies.
- Invests in research and development to explore new psychedelic compounds.
- Expands its network of health centers across North America and Europe.
- Develops proprietary psychedelic molecules for therapeutic use.
Business Model
- Generates revenue by providing psychedelic-assisted therapy services at its health centers.
- Invests in research and development to create proprietary psychedelic molecules.
- Seeks strategic partnerships and collaborations to expand its reach and capabilities.
Industry Context
Field Trip Health & Wellness Ltd. operates within the rapidly evolving biotechnology industry, specifically targeting the emerging market for psychedelic therapies. This market is characterized by increasing interest in alternative mental health treatments and growing acceptance of psychedelic substances for therapeutic use. The competitive landscape includes companies like AWKNF (Awakn Life Sciences Corp.), BRRGF (Braxia Scientific Corp.), DOGP (atai Life Sciences N.V.), HERTF (Cybin Inc.), and IPCIF (Revive Therapeutics Ltd.), all exploring various approaches to psychedelic medicine. The industry faces regulatory hurdles and requires significant investment in research and clinical trials. Market trends indicate a growing demand for innovative mental health solutions, positioning Field Trip to potentially benefit from this trend.
Key Customers
- Individuals suffering from mental health conditions such as depression, anxiety, and PTSD.
- Patients seeking alternative treatments for mental health disorders.
- Healthcare providers and institutions interested in offering psychedelic therapies.
Financials
Chart & Info
Field Trip Health & Wellness Ltd. (FTHWF) stock price: Price data unavailable
Latest News
No recent news available for FTHWF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for FTHWF.
Price Targets
Wall Street price target analysis for FTHWF.
MoonshotScore
What does this score mean?
The MoonshotScore rates FTHWF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Ronan Levy
CEO
Ronan Levy is the CEO of Field Trip Health & Wellness Ltd. He has a background in law and business, with experience in the cannabis and psychedelic industries. Prior to joining Field Trip, he co-founded Canadian Cannabis Clinics and CanvasRx, which were acquired by Aurora Cannabis. Levy has been involved in the development and implementation of innovative healthcare models and has a strong focus on patient care and access to treatment. His expertise includes regulatory compliance, business development, and strategic planning.
Track Record: Under Ronan Levy's leadership, Field Trip Health & Wellness Ltd. has established a network of health centers providing psychedelic therapies in North America and Europe. He has overseen the company's research and development efforts, including the development of proprietary psychedelic molecules. Key milestones include the expansion of the company's clinical infrastructure and the advancement of its clinical trial programs. Levy has also been instrumental in securing funding and establishing strategic partnerships.
FTHWF OTC Market Information
The OTC Other tier, where Field Trip Health & Wellness Ltd. trades, represents the lowest tier of the OTC market. Companies in this tier often have limited financial disclosure and may not meet minimum listing requirements. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements, resulting in higher risk for investors. These companies may be early-stage ventures, distressed businesses, or foreign entities with limited U.S. presence. Investors should exercise extreme caution and conduct thorough due diligence before investing in OTC Other stocks.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in FTHWF.
- Lower trading volumes and wider bid-ask spreads can lead to price volatility.
- OTC Other listing indicates a higher risk profile compared to stocks on major exchanges.
- Potential for limited regulatory oversight and investor protection.
- Dependence on the company's ability to secure funding and achieve commercial success.
- Verify the availability and reliability of financial information.
- Assess the company's management team and their track record.
- Review the company's business plan and growth strategy.
- Evaluate the competitive landscape and the company's market position.
- Understand the regulatory environment and potential risks.
- Assess the liquidity of the stock and potential trading challenges.
- Consult with a financial advisor before making any investment decisions.
- Operation of health centers providing psychedelic therapies.
- Focus on research and development of proprietary molecules.
- Experienced management team with expertise in biotechnology and healthcare.
- Strategic partnerships and collaborations with other organizations.
- Presence in the emerging psychedelic therapy market.
What Investors Ask About Field Trip Health & Wellness Ltd. (FTHWF)
What does Field Trip Health & Wellness Ltd. do?
Field Trip Health & Wellness Ltd. operates health centers that provide psychedelic therapies for mental health conditions such as depression, anxiety, and PTSD. The company combines psychedelic substances, such as psilocybin and ketamine, with psychotherapy to enhance treatment outcomes. Field Trip's business model involves generating revenue through the provision of these therapies at its health centers, as well as investing in research and development to create proprietary psychedelic molecules. The company aims to establish itself as a leader in the emerging field of psychedelic medicine, providing innovative and effective treatments for mental health disorders.
What do analysts say about FTHWF stock?
As of 2026-03-18, there is limited analyst coverage on Field Trip Health & Wellness Ltd. (FTHWF) due to its OTC listing and relatively small market capitalization. The company's valuation is highly speculative, reflecting the early stage of the psychedelic therapy market and the uncertainty surrounding regulatory approvals. Growth considerations include the expansion of its health center network and the development of proprietary psychedelic molecules. Investors should conduct thorough due diligence and consider the risks associated with investing in OTC stocks before making any investment decisions. No buy or sell recommendations are available.
What are the main risks for FTHWF?
The main risks for Field Trip Health & Wellness Ltd. include regulatory hurdles, competition from other biotechnology companies, and potential adverse side effects associated with psychedelic substances. The evolving legal landscape and the need for regulatory approvals in various jurisdictions pose significant challenges. Competition from established pharmaceutical companies and other biotech firms in the psychedelic therapy market could limit the company's market share. Additionally, negative public perception and stigma associated with psychedelic treatments could hinder adoption and growth. The company's dependence on securing funding and achieving commercial success also presents a significant risk.
What are the key factors to evaluate for FTHWF?
Field Trip Health & Wellness Ltd. (FTHWF) currently holds an AI score of 38/100, indicating low score. Key strength: First-mover advantage in the psychedelic therapy market.. Primary risk to monitor: Potential: Regulatory hurdles and evolving legal landscape could delay or prevent market expansion.. This is not financial advice.
How frequently does FTHWF data refresh on this page?
FTHWF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven FTHWF's recent stock price performance?
Recent price movement in Field Trip Health & Wellness Ltd. (FTHWF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: First-mover advantage in the psychedelic therapy market.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider FTHWF overvalued or undervalued right now?
Determining whether Field Trip Health & Wellness Ltd. (FTHWF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying FTHWF?
Before investing in Field Trip Health & Wellness Ltd. (FTHWF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data available due to OTC listing.
- Analyst coverage is sparse, making independent assessment challenging.
- The psychedelic therapy market is nascent and subject to regulatory changes.